Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, Vitamins B6 and B12

被引:66
作者
Till, U
Röhl, P
Jentsch, A
Till, H
Müller, A
Bellstedt, K
Plonné, D
Fink, HS
Vollandt, R
Sliwka, U
Herrmann, FH
Petermann, H
Riezler, R
机构
[1] Univ Jena, Inst Pathobiochem, D-07740 Jena, Germany
[2] Catholic Hosp, Clin Int Med, Erfurt, Germany
[3] Univ Jena, Neurol Clin, Jena, Germany
[4] Univ Jena, Clin Internal Med, Jena, Germany
[5] Univ Jena, Inst Clin Chem, Jena, Germany
[6] Univ Jena, Inst Med Stat, Jena, Germany
[7] Eppendorf Univ Hosp, Neurol Clin, Hamburg, Germany
[8] Univ Greifswald, Inst Human Genet, Greifswald, Germany
[9] Severi Med, Munster, Germany
关键词
atherosclerosis; cerebral ischemia; homocysteine; intima-media thickness; vitamin supplementation;
D O I
10.1016/j.atherosclerosis.2004.12.043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Hyperhomocysteinemia is associated with atherosclerotic risk. Although vitamins can lower homocysteine (Hcy), information about effects on atherosclerosis is scarce. Methods: We used carotid intima-media thickness (IMT) as an accepted marker of atherosclerotic changes. Fifty patients (60 +/- 8 years) with IMT > 1 mm were included. In a double blind, randomized trial they received daily 2.5 mg folic acid, 25 mg Vitamin B6, and 0.5 mg Vitamin B12 or placebo for 1 year. Results: In the treatment group, Hcy decreased from 10.50 +/- 3.93 to 6.56 +/- 1.53 mu mol/l (P < 0.0001), whereas it remained unchanged in the placebo group (10.76 +/- 2.36 versus 10.45 +/- 3.30 mu mol/l). IMT decreased from 1.50 +/- 0.44 to 1.42 +/- 0.48 mm (P = 0.034) in the treatment group, whereas it increased from 1.47 +/- 0.57 to 1.54 +/- 0.71 mm in the placebo group. The mean individual changes of IMT between both groups differed significantly (-0.08 +/- 0.17 versus 0.07 +/- 0.25 mm, P = 0.019). Multiple regression analysis revealed that the observed effect on IMT depended only on medication. Conclusions: Vitamin supplementation significantly reduces IMT in patients at risk. This effect is independent of Hcy concentration. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:131 / 135
页数:5
相关论文
共 27 条
[1]   SERUM BETAINE, N,N-DIMETHYLGLYCINE AND N-METHYLGLYCINE LEVELS IN PATIENTS WITH COBALAMIN AND FOLATE-DEFICIENCY AND RELATED INBORN-ERRORS OF METABOLISM [J].
ALLEN, RH ;
STABLER, SP ;
LINDENBAUM, J .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (11) :1448-1460
[2]   Correlates of plasma homocysteine, cysteine and cysteinyl-glycine in respondents in the British National Diet and Nutrition Survey of Young People Aged 4-18 Years, and a comparison with the Survey of People Aged 65 Years and Over [J].
Bates, CJ ;
Mansoor, MA ;
Gregory, J ;
Pentieva, K ;
Prentice, A .
BRITISH JOURNAL OF NUTRITION, 2002, 87 (01) :71-79
[3]   Ultrasound morphology classification of the arterial wall and cardiovascular events in a 6-year follow-up study [J].
Belcaro, G ;
Nicolaides, AN ;
Laurora, G ;
Cesarone, MR ;
DeSanctis, M ;
Incandela, L ;
Barsotti, A .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (07) :851-856
[4]   Vitamin supplementation reduces blood homocysteine levels - A controlled trial in patients with venous thrombosis and healthy volunteers [J].
den Heijer, M ;
Brouwer, IA ;
Bos, GMJ ;
Blom, HJ ;
van der Put, NMJ ;
Spaans, AP ;
Rosendaal, FR ;
Thomas, CMG ;
Haak, HL ;
Wijermans, PW ;
Gerrits, WBJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (03) :356-361
[5]   Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering [J].
Doshi, SN ;
McDowell, IFW ;
Moat, SJ ;
Payne, N ;
Durrant, HJ ;
Lewis, MJ ;
Goodfellow, J .
CIRCULATION, 2002, 105 (01) :22-26
[6]   A CANDIDATE GENETIC RISK FACTOR FOR VASCULAR-DISEASE - A COMMON MUTATION IN METHYLENETETRAHYDROFOLATE REDUCTASE [J].
FROSST, P ;
BLOM, HJ ;
MILOS, R ;
GOYETTE, P ;
SHEPPARD, CA ;
MATTHEWS, RG ;
BOERS, GJH ;
DENHEIJER, M ;
KLUIJTMANS, LAJ ;
VANDENHEUVEL, LP ;
ROZEN, R .
NATURE GENETICS, 1995, 10 (01) :111-113
[7]   Plasma homocysteine as a risk factor for vascular disease - The European concerted action project [J].
Graham, IM ;
Daly, LE ;
Refsum, HM ;
Robinson, K ;
Brattstrom, LE ;
Ueland, PM ;
PalmaReis, RJ ;
Boers, GHJ ;
Sheahan, RG ;
Israelsson, B ;
Uiterwaal, CS ;
Meleady, R ;
McMaster, D ;
Verhoef, P ;
Witteman, J ;
Rubba, P ;
Bellet, H ;
Wautrecht, JC ;
deValk, HW ;
Luis, ACS ;
ParrotRoulaud, FM ;
Tan, KS ;
Higgins, I ;
Garcon, D ;
Medrano, MJ ;
Candito, M ;
Evans, AE ;
Andria, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (22) :1775-1781
[8]   Keep young and beautiful [J].
Greenwood, E .
NATURE REVIEWS CANCER, 2001, 1 (01) :6-6
[9]   What level of plasma homocyst(e)ine should be treated?: Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 μmol/L [J].
Hackam, DG ;
Peterson, JC ;
Spence, JD .
AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (01) :105-110
[10]   Correlation between flow-mediated vasodilatation of the brachial artery and intima-media thickness in the carotid artery in men [J].
Hashimoto, M ;
Eto, M ;
Akishita, M ;
Kozaki, K ;
Ako, J ;
Iijima, K ;
Kim, S ;
Toba, K ;
Yoshizumi, M ;
Ouchi, Y .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (11) :2795-2800